Algorithm may help better predict how likely it is a woman will have cancer in her future.
A deep learning (DL) algorithm can help assess mammographic breast density equal to that of an experienced mammographer, according to a study published in the journal Radiology.
Researchers from Harvard Medical School in Boston and the Massachusetts Institute of Technology in Cambridge, performed a retrospective study to assess the utility and accuracy of such a DL algorithm in reading mammograms.
“We’re dependent on human qualitative assessment of breast density, and that approach has significant flaws,” lead author Constance D. Lehman, MD, PhD, said in a release. “We need a more accurate tool.”
The researchers trained a deep convolutional neural network to assess Breast Imaging Reporting and Data System (BI-RADS) breast density based on the original interpretation by an experienced radiologist of 41,479 digital screening mammograms obtained in 27,684 women. The resulting algorithm was tested on a held-out test set of 8,677 mammograms in 5,741 women. In addition, five radiologists performed a reader study on 500 mammograms randomly selected from the test set.
Related article: How AI Affects Your Finances
The algorithm was then implemented in routine clinical practice, where eight radiologists reviewed 10,763 consecutive mammograms assessed with the model. Agreement on BI-RADS category for the DL model and for three sets of readings were performed by:
The results showed that the DL model showed good agreement with the radiologists in the test set and with radiologists in consensus in the reader study set. There was very good agreement with radiologists in the clinical implementation set.
DL assessments were accepted by the interpreting radiologists for binary categorization of dense or nondense breasts (10,149 of 10,763; 94%)-however, the researchers pointed out that the 6% disagreement was not necessarily machine-error but reader variability.
“The study results show that the algorithm worked remarkably well,” coauthor Regina Barzilay, PhD, a professor of computer science and electrical engineering said in the release. “But what’s more important is that it is being used every day to measure breast density in mammograms at a major hospital.”
The algorithm has the potential to standardize and automate routine breast density assessment, the researchers said. On a broader scale, they see AI as central to the development of personalized breast cancer risk assessment for each woman who undergoes mammography.
AI is uniquely suited to breast imaging because it can draw upon a large, mature database with advanced, structured reporting that links images with outcomes. This predictive power is a potential boon to all women, including groups who have been inadequately served by current prediction models. For instance, research has shown that current predictive models tend to underestimate risk in African-American women.
“With AI, we now have the ability to leverage vast amounts of information into more personalized, more targeted care for our patients,” Lehman said. “In the case of breast cancer, we can better predict how likely a woman will have cancer in her future and improve the chances that it will be treated successfully.”
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.